Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

ClinicalTrials.gov ID: NCT01392573

Public ClinicalTrials.gov record NCT01392573. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin degludec (IDeg) in subjects with type 2 diabetes. Subjects continue their pre-trial treatment with metformin throughout the entire trial.

Study identification

NCT ID
NCT01392573
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
413 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 28, 2011 (Actual)
Primary completion
Oct 1, 2012 (Actual)
Completion
Oct 4, 2012 (Actual)
Last update posted
Jan 3, 2019

2011 – 2012

United States locations

U.S. sites
58
U.S. states
23
U.S. cities
52
Facility City State ZIP Site status
Novo Nordisk Investigational Site Huntsville Alabama 35801 —
Novo Nordisk Investigational Site Vestavia Hills Alabama 35209 —
Novo Nordisk Investigational Site Anaheim California 92801 —
Novo Nordisk Investigational Site Los Angeles California 90057 —
Novo Nordisk Investigational Site Tustin California 92780 —
Novo Nordisk Investigational Site Ventura California 93003 —
Novo Nordisk Investigational Site Colorado Springs Colorado 80910 —
Novo Nordisk Investigational Site Waterbury Connecticut 06708 —
Novo Nordisk Investigational Site Melbourne Florida 32934 —
Novo Nordisk Investigational Site Miami Florida 33156 —
Novo Nordisk Investigational Site Roswell Georgia 30076 —
Novo Nordisk Investigational Site Arlington Heights Illinois 60004-2315 —
Novo Nordisk Investigational Site Avon Illinois 46123 —
Novo Nordisk Investigational Site Chicago Illinois 60607 —
Novo Nordisk Investigational Site Crystal Lake Illinois 60012 —
Novo Nordisk Investigational Site Gurnee Illinois 60031 —
Novo Nordisk Investigational Site Greenfield Indiana 46140 —
Novo Nordisk Investigational Site Indianapolis Indiana 46254 —
Novo Nordisk Investigational Site Muncie Indiana 47304 —
Novo Nordisk Investigational Site New Albany Indiana 47150 —
Novo Nordisk Investigational Site Lexington Kentucky 40503 —
Novo Nordisk Investigational Site Metairie Louisiana 70002 —
Novo Nordisk Investigational Site Metairie Louisiana 70006-2930 —
Novo Nordisk Investigational Site Slidell Louisiana 70461-4231 —
Novo Nordisk Investigational Site Rockville Maryland 20852 —
Novo Nordisk Investigational Site Methuen Massachusetts 01844 —
Novo Nordisk Investigational Site North Dartmouth Massachusetts 02747 —
Novo Nordisk Investigational Site Waltham Massachusetts 02453 —
Novo Nordisk Investigational Site Southfield Michigan 48034-7661 —
Novo Nordisk Investigational Site Chesterfield Missouri 63017 —
Novo Nordisk Investigational Site Saint Charles Missouri 63303 —
Novo Nordisk Investigational Site Nashua New Hampshire 03063 —
Novo Nordisk Investigational Site Lawrenceville New Jersey 08648 —
Novo Nordisk Investigational Site Toms River New Jersey 08755-8050 —
Novo Nordisk Investigational Site Albany New York 12206 —
Novo Nordisk Investigational Site Smithtown New York 11787 —
Novo Nordisk Investigational Site Asheboro North Carolina 27203 —
Novo Nordisk Investigational Site Chapel Hill North Carolina 27517 —
Novo Nordisk Investigational Site Greensboro North Carolina 27408 —
Novo Nordisk Investigational Site Hickory North Carolina 28602 —
Novo Nordisk Investigational Site Statesville North Carolina 28625 —
Novo Nordisk Investigational Site Beaver Pennsylvania 15009 —
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19107 —
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19152 —
Novo Nordisk Investigational Site Greer South Carolina 29651 —
Novo Nordisk Investigational Site Simpsonville South Carolina 29681 —
Novo Nordisk Investigational Site Nashville Tennessee 37203 —
Novo Nordisk Investigational Site Arlington Texas 76014 —
Novo Nordisk Investigational Site Austin Texas 78731 —
Novo Nordisk Investigational Site Dallas Texas 75230 —
Novo Nordisk Investigational Site Dallas Texas 75246 —
Novo Nordisk Investigational Site Dallas Texas 75251 —
Novo Nordisk Investigational Site Hurst Texas 76054 —
Novo Nordisk Investigational Site San Antonio Texas 78215 —
Novo Nordisk Investigational Site San Antonio Texas 78224 —
Novo Nordisk Investigational Site San Antonio Texas 78229 —
Novo Nordisk Investigational Site Sugar Land Texas 77478 —
Novo Nordisk Investigational Site Salt Lake City Utah 84107 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01392573, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 3, 2019 · Synced Oct 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01392573 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →